Our cell engineering and Development services cater to both tool or reagent and biological product development requirements. We have strong expertise to generate recombinant or stable cell lines for complex and wide protein class targets such as:
RTKs GPCRs Ion channels Immune modulation ligands or receptors Fc-gamma receptors GPI-anchored TNF-receptor superfamily Cell adhesion molecules Transporters Co-receptors Reporter genes
We are well-versed in working with different cellular backgrounds such as established cancer cell lines and primary cells. Hard-to-transfect cell lines required for binding studies, functional assays, immunization in vitro or in vivo screening and efficacy evaluation applications are successfully engineered to achieve the desired attributes.
For biologics programs, we have experience of product development for mAbs, immune-fusion molecules and cytokines. The typical activities includes: transfection, selection, Limiting dilution, media/feed screening, cell line characterization, research cell banking and protein production
pcDNA series, pLVX and pGIPZ / pTRIPZ lentiviral vector series, pCHO1.0, pOptivec, pGL and in-house modified vector systems
Strong framework data recording and traceability
Recombinant cell lines for wide protein classes
In-house lentiviral platform for difficult to express reagent proteins
Extensive experience working with various vector or cell line systems
APRIL 24, 2023
Both natural and unnatural catastrophic events inflict negative consequences due to the ever-increasing interconnectedness of the global economy. Those consequences are certain to last for longer duration. e.g.; The Covid-19 pandemic is still having a negative impact on the global economy. Maintaining continuity is critical for all businesses, but perhaps no othe...Read More
The pharma industry is evolving and a demand for integrated CDMOs, which can help accelerating innovations, is part of the evolution....Read More
Introduction: An orally-available anti-diabetic candidate that simultaneously targets all three key organs of diabetes: Pancreas, Liver and Muscles. This drug targets the two main defects seen in patients with type 2 diabetes: The pancreas by increasing insulin secretion, in a glucose-dependent manner; and the muscles and liver by decreasing the excess production...Read More
The combination of CuI–K2CO3-PEG 400 facilitated the couplingcyclization of o-iodobenzoic acid with terminal alkynes under ultrasound, affording a greener and practical approach towards 3-substituted isocoumarins with remarkable regioselectivity. This inexpensive and Pd and ligand free methodology gave rise to various isocoumarins of potential pharmacological i...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Cholecalciferol, also known as Vitamin D3, is widely prescribed for the treatment osteomalacia and osteoporosis . It also plays a key role in calcium and phosphorus homeostasis and skeletal mineralization . IUPAC name of Cholecalciferol is (3β, 5Z, 7E)- 9,10-secocholesta-5,7,10(19)-trien-3-ol, whose molecular weight is 384.64 g/mol and its molecular formul...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.